anaplastic oligodendroglioma (Cancer)
Information
- Disease name
- anaplastic oligodendroglioma
- Disease ID
- DOID:7154
- Description
- "An oligodendroglioma that is characterized by focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity)." [url:https\://en.wikipedia.org/wiki/Anaplastic_oligodendroglioma, url:https\://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma, url:https\://www.cancer.gov/rare-brain-spine-tumor/tumors/oligodendroglioma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05934630 | Active, not recruiting | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | July 12, 2023 | July 12, 2028 | |
| NCT04295759 | Active, not recruiting | Phase 1 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | July 27, 2020 | June 30, 2024 |
| NCT02101905 | Active, not recruiting | Phase 1 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | March 13, 2014 | October 19, 2024 |
| NCT00362570 | Completed | Phase 2 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | May 2005 | March 2011 |
| NCT00390299 | Completed | Phase 1 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | October 23, 2006 | November 30, 2019 |
| NCT00667394 | Completed | Phase 2 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | April 2008 | July 2011 |
| NCT00734682 | Completed | Phase 1 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | August 2008 | December 2014 |
| NCT00884416 | Completed | Phase 1 | Sorafenib in Newly Diagnosed High Grade Glioma | March 2009 | March 2012 |
| NCT00995007 | Completed | Phase 2 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | September 2009 | December 2015 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT00004688 | Completed | Phase 2 | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms | August 1996 | July 1998 |
| NCT00064779 | Completed | Phase 1 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | July 2003 | July 2007 |
| NCT00303849 | Completed | Phase 1/Phase 2 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | September 15, 2005 | March 12, 2021 |
| NCT01144247 | Completed | Phase 1 | Cellular Immunotherapy Study for Brain Cancer | July 2010 | July 2015 |
| NCT01156584 | Completed | Phase 1 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | July 2010 | August 18, 2016 |
| NCT01250470 | Completed | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | September 5, 2012 | May 29, 2014 |
| NCT01316809 | Completed | Phase 1 | AZD8055 for Adults With Recurrent Gliomas | March 4, 2011 | April 4, 2016 |
| NCT01380782 | Completed | Phase 2 | BIBF 1120 for Recurrent High-Grade Gliomas | May 2012 | July 2014 |
| NCT01470794 | Completed | Phase 1 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | February 2012 | April 12, 2016 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT01847235 | Completed | Phase 2 | Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | May 2013 | March 2016 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT01985256 | Completed | Phase 1 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | February 2014 | March 3, 2016 |
| NCT02238496 | Completed | Phase 1 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | December 8, 2014 | February 14, 2021 |
| NCT02644291 | Completed | Phase 1 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | May 2016 | June 9, 2022 |
| NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
| NCT02871843 | Completed | Phase 1 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas | February 14, 2017 | September 19, 2021 |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT03072134 | Completed | Phase 1 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | April 24, 2017 | July 1, 2021 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT02755987 | No longer available | Expanded Access to ANG1005 for Individual Patients | |||
| NCT04135807 | Recruiting | Early Phase 1 | Implantable Microdevice In Primary Brain Tumors | March 3, 2020 | February 1, 2024 |
| NCT04623931 | Recruiting | Phase 2 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | January 30, 2020 | December 31, 2026 |
| NCT04047264 | Recruiting | N/A | Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | January 1, 2020 | September 1, 2027 |
| NCT04978727 | Recruiting | Phase 1 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | July 1, 2022 | June 30, 2028 |
| NCT05698524 | Recruiting | Phase 1 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | June 26, 2023 | June 2027 |
| NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
| NCT06108206 | Recruiting | N/A | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | January 30, 2024 | December 31, 2026 |
| NCT03975829 | Recruiting | Phase 4 | Pediatric Long-Term Follow-up and Rollover Study | November 4, 2019 | May 29, 2026 |
| NCT01849952 | Recruiting | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | February 28, 2020 | May 2024 | |
| NCT00062504 | Terminated | Phase 2 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | July 2003 | April 2006 |
| NCT01721577 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | December 2012 | December 2015 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT02168270 | Terminated | Phase 1 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | June 16, 2014 | August 20, 2015 |
| NCT03971734 | Terminated | Phase 1 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | December 6, 2019 | October 2, 2023 |
| NCT01281982 | Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | January 13, 2011 | September 24, 2012 | |
| NCT01656980 | Unknown status | Phase 3 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | August 2012 | December 2014 |
| NCT01637753 | Unknown status | N/A | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | June 2012 | December 2013 |
| NCT00734864 | Withdrawn | Phase 1 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | June 2009 | June 2012 |
| NCT00645385 | Withdrawn | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme. | June 2007 | June 1, 2011 | |
| NCT03353896 | Withdrawn | N/A | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | December 15, 2017 | December 8, 2020 |
- Disase is a (Disease Ontology)
- DOID:3181
- Cross Reference ID (Disease Ontology)
- NCI:C4326